Cancer Diagnostics Partnering Terms and Agreements 2014-2020 - ResearchAndMarkets.com

DUBLIN--()--The "Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. It provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2014.

  • Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2014
  • Analysis of Cancer Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Cancer Diagnostics deals
  • Access to Cancer Diagnostics contract documents
  • Leading Cancer Diagnostics deals by value since 2014
  • Most active Cancer Diagnostics dealmakers since 2014

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 800 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking.

  • Chapter 1 provides an introduction to the report, whilst Chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announced by that company, as well as contract documents, where available.
  • Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2014. The Chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

  • 3D Signatures
  • 3PrimeDx
  • 14M Genomics
  • 20/20 GeneSystems
  • 1717 Life Science Ventures
  • AB Analitica
  • Abbott Laboratories
  • Abbvie
  • Abcodia
  • Abramson Cancer Center
  • AccuGenomics
  • Accuray
  • Accu Reference Medical Laboratory
  • AceCGT Life Science
  • Acoustic MedSystems
  • ACT Genomics
  • Adaptiiv
  • Adaptive Biotechnologies
  • ADC Therapeutics
  • Admera Health
  • Advanced Accelerator Applications
  • Advanced Cell Diagnostics
  • Advanced Cooling Therapy
  • Advanced Nuclear Medicine Ingredients
  • Aelan Cell Technologies
  • Aetna
  • Agena Bioscience
  • Agendia
  • Agilent Technologies
  • Agios Pharmaceuticals
  • AG Mednet
  • Albert Einstein Healthcare Network
  • Alibaba Health
  • Alliance Global FZ
  • Alliance Global Group
  • Almac Diagnostics
  • Almac Group
  • Alpha Imaging
  • Alteris
  • Amarantus BioSciences
  • Ambry Genetics
  • America's Choice Provider Network
  • American Health Imaging
  • American Lung Association
  • Amgen
  • Amoy Diagnostics
  • AmoyDx Diagnostics
  • Amplitech
  • Analogic
  • Angle
  • Angsana Molecular & Diagnostics
  • Anixa Biosciences
  • Anpac Bio-Medical Science
  • Anthem Bluecross
  • Apogenix
  • Appistry
  • Arbor Vita
  • ArcherDX
  • Arc Medical Design
  • Areva Med
  • Arno Therapeutics
  • AroCell
  • Arquer Diagnostics
  • Array Biopharma
  • Arrow Diagnostics
  • ASPiRA Labs
  • Aspira Scientific
  • Astellas Pharma
  • AstraZeneca
  • Asuragen
  • Austrian Institute of Technology
  • Avant Diagnostics
  • Avantis Medical Systems
  • AVEO Oncology
  • Avera Heart Hospital of South Dakota
  • Axela
  • Axella Research
  • Aytu BioScience
  • Bayer
  • Bayer Healthcare
  • Baylor Genetics
  • Beckman Coulter
  • BeiGene
  • Bertech Diagnostics
  • Bertin Pharma
  • Beyondspring Pharmaceuticals
  • bioAffinity Technologies
  • Biocartis
  • Biocept
  • BioChain
  • Biodesix
  • BioGemex
  • Biognosys
  • Biohealth Innovation
  • BioLizard
  • Biological Dynamics
  • BioMark Diagnostics
  • BioMarker Strategies
  • Biomedical Advanced Research and Development Authority
  • bioMerieux
  • BioNano Genomics
  • BioNova Cientifica
  • Biopsy Sciences
  • Biotech-IgG
  • BioTheranostics
  • BioVendor
  • Biovica
  • Bioyong
  • BL&H
  • Black Swan Research Initiative
  • Bliss Biopharmaceutical
  • BloodCenter Of Wisconsin
  • Bluebee
  • Blue Cross Blue Shield Association
  • BlueCross BlueShield of Tennessee
  • Blue Earth Diagnostics
  • Blueprint Medicines
  • Boehringer Ingelheim
  • Bonnie J. Addario Lung Cancer Foundation
  • Boreal Genomics
  • BostonGene
  • Bostwick Laboratories
  • Bpifrance
  • Bracco Imaging
  • Breath Diagnostics
  • Brigham and Women's Hospital
  • Bristol-Myers Squibb
  • Bristol-Myers Squibb Pakistan
  • Broad Institute
  • Bruker
  • Buck Institute for Age Research
  • Burning Rock
  • Butantan Institute
  • C4 Imaging
  • Caliber Imaging & Diagnostics
  • Cambridge Epigenetix
  • CANbridge Life Sciences
  • Cancer Genetics
  • Cancer Prevention and Research Institute of Texas
  • Cancer Research Institute
  • Cancer Research UK
  • Cancer Targeted Technology
  • Capital X-ray
  • Caprion Proteomics
  • Cardinal Health
  • Care GB Plus
  • Carestream Health
  • Caris Life Sciences
  • CarThera
  • Case Western Reserve University
  • Catholic University Leuven
  • CBD Vida
  • CBLPath
  • CDx Diagnostics
  • Celgene
  • Cellgen Diagnostics
  • CellSight Technologies
  • Cell Signaling Technology
  • Celsee
  • Celsion
  • Celsius Therapeutics
  • Celtic Biotech
  • Center for Connected Health
  • Centogene
  • Centre for Imaging Technology Commercialization
  • Centre for Probe Development and Commercialization
  • Centre Leon Berard
  • Cerba HealthCare

For more information about this report visit https://www.researchandmarkets.com/r/ejxq1y

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900